In the context of cancer, CHK1 is often overexpressed or dysregulated, contributing to the survival of cancer cells despite their high levels of DNA damage. Cancer cells exploit CHK1 to bypass normal cell cycle controls, allowing them to proliferate uncontrollably. Thus, CHK1 is considered a potential target for cancer therapy, as inhibiting its function can sensitize cancer cells to DNA-damaging agents and induce cell death.
